- Sio Gene Therapies, Inc. (formerly
known as
Axovant Gene Therapies) was a clinical-stage
pharmaceutical company that
developed gene
therapies to treat...
-
negative results. Consequently,
Axovant announced in 2018 that it has
discontinued development of this drug. "Intepirdine -
Axovant Sciences / GlaxoSmithKline"...
-
Roivant subsidiary Axovant Sciences in an
attempt to
market intepirdine as a drug for Alzheimer's disease. In
December 2014,
Axovant purchased the patent...
- As of
February 2023, Roivant's
reported market cap was over $6 billion.
Axovant,
owned by Roivant's Sio Gene Therapies,
which failed testing in the end...
-
nelotanserin was
repurposed for the
treatment of Lewy body
dementia (LBD) by
Axovant Sciences (now Sio Gene Therapies). In late 2018, the
company announced...
-
Limited AXS.PRD
Bermuda Axis
Capital Holdings Limited AXS.PRE
Bermuda Axovant Sciences Ltd. AXON
Bermuda Azure Power Global Ltd. AZRE
India AZZ incorporated...
- Parkinson's
disease became the
subject of a
commercialization deal with
Axovant Sciences. In May 2019, the
company announced an
investment by Novo Holdings...
-
Sciences Angion Biomedica Applied DNA
Sciences Armgo Pharma Axios Oncology Axovant Sciences Azure Biotech AzurRx Biopharma Bantam Pharmaceutical Bioreclamation...
-
September 2016). "PhIII Alzheimer's flop
takes chunk out of Lundbeck, hits
Axovant with aftershocks".
Lundbeck expands its
pipeline -
initiating phase II...
- the Lewy Body Society, Alzheimer’s ****ociation,
Acadia Pharmaceuticals,
Axovant Sciences,
Banner Health, GE Healthcare, and Lundbeck. The 2015 DLBC in...
